Trilostane

Trilostane (Win 24540) is a competitive and orally active 3-β-hydroxysteroiddehydrogenase (3β-HSD) inhibitor. Trilostane is a synthetic nonhormonal steroid. Trilostane can be used for the research of breast cancer and prostate cancer[1][2].

Product Specifications

CAS Number

[13647-35-3]

Product Name Alternative

Win 24540

UNSPSC

12352005

Hazard Statement

H315, H319, H361

Target

3β-HSD

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Endocrinology; Cancer

Assay Protocol

https://www.medchemexpress.com/Trilostane.html

Purity

99.81

Solubility

DMSO : ≥ 56 mg/mL

Smiles

OC1=C(C#N)C[C@@]2(C)[C@@]3(CC[C@]4([H])[C@]2([H])CC[C@@]5(C)[C@@]4([H])CC[C@@H]5O)[C@@H]1O3

Molecular Formula

C20H27NO3

Molecular Weight

329.43

Precautions

H315, H319, H361

References & Citations

[1]JA Braddock, et al. Trilostane treatment in dogs with pituitary-dependent hyperadreno-corticism. Veterinary Journal. 10 March 2008.|[2]Ouschan C, et al. The influence of trilostane on steroid hormone metabolism in canine adrenal glands and corpora lutea-an in vitro study. Vet Res Commun. 2012 Mar;36 (1) :35-40.